Lumiracoxib is an effective alternative to traditional non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of post-operative pain.

The main purpose of this study was to investigate judgments made by employees from the pharmaceutical industry and allied health‐care sectors in a set of four different drug discovery and development cases derived from real scenarios. Each case study related to go/no‐go decisions taken from various steps in drug discovery through preclinical and clinical development (investigational new drug) on to market introduction (new drug application) and treatment of the target population. Using a web‐based questionnaire, 52 respondents made five sets of judgment within each drug case whether to continue or halt further project development. For each case, additional details of the developmental scenario were disclosed to the respondent after completion of each judgment response. We also assessed to what extent the individual judgments given by the respondents were influenced by work experience and functional role, education, or their perceived entrepreneurial character. Our study demonstrates that health‐care employees differ substantially in their individual intuitive judgments of benefit and risk in go/no‐go decisions during the drug discovery and development process. This lack of coherence and wide variability with respect to the drug development cases selected may reflect judgment in the real world. Such judgments are usually taken from incomplete information, and individual decision‐making rules vary substantially between experts in the field. Further knowledge about this inherent human functional judgment variability may be helpful to form a better understanding of individual decision‐making in relation to inherent uncertainties. Additional research may also clarify how personal experience within drug discovery and development influences judgment and help to optimize decision outcomes in the drug development sector. Importantly, a deeper insight of the fundamentals and rules that shape individual and group decision‐making of everyday drug discovery and development may help to optimize the decision processes in the pharmaceutical industry.

No abstract

No abstract

We used a web-based questionnaire survey to investigate how employees from the pharmaceutical and allied health industries perceive the importance of different steps within drug research and development for assessing the benefits and risks of developmental drugs to reach market registration and enter into clinical use. Key outcomes were that Pharmaceutical Processes were seen as least important while Toxicology was most important followed by Clinical Trials Phases 2 Late/3, Safety and Pharmacovigilance, and Clinical Trials Phase 2 Early. Nonparametric analysis showed that these outcomes were influenced by demographics of the selected employee target population. Since this survey was exploratory, we feel the expressed judgments of the study population are important for planning research surveys using more complex scenarios to investigate intuitive perception of risks and benefits in drug research and development.